Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Exp Hematol ; 40(9): 698-704.e2, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22659385

ABSTRACT

Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have traditionally been considered as two distinct entities. However, there are rare reports of patients that, over time, develop both diseases. It remains unresolved whether the origin of the two diseases is from the same clone. In this study, we attempted to retrospectively investigate the clinical and molecular aspects of patients who developed both lymphomas. The rearranged immunoglobulin heavy-chain variable region genes from both diagnoses were compared to each other. Twenty-six patients presented with both diagnoses. Twelve had HL as the primary disorder ("HL first" group) and the majority of these (75%) presented with aggressive lymphoma as the second lymphoma. In contrast, in the 11 patients for whom NHL was the primary disorder ("NHL first" group), this was usually (82%) of low-grade histology. Three patients were diagnosed concurrently with both diseases. Mean age at first diagnosis was higher (p = 0.037) in the NHL first group (56.1 years) than in the HL first group (40 years). Mean time between diagnoses was longer (p = 0.026) in the HL first group (9 years) than in the NHL first group (5 years). For 11 patients, diagnostic samples were available for molecular analyses from both diagnoses of HL and NHL. In 6 of these 11 patients, gene rearrangement studies were informative. No patient had the same gene rearrangement identified in both diseases. It seems that development of HL and NHL in one patient, at different time points, reflects, in many cases, separate biologic diseases.


Subject(s)
Clone Cells/pathology , Hodgkin Disease/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Adult , Aged , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Clone Cells/immunology , Clone Cells/metabolism , DNA, Neoplasm/analysis , DNA, Neoplasm/genetics , Endoplasmic Reticulum Chaperone BiP , Female , Gene Rearrangement , Heat-Shock Proteins/genetics , Hodgkin Disease/genetics , Hodgkin Disease/immunology , Humans , Immunoglobulin Variable Region/genetics , Lymphoma, Non-Hodgkin/genetics , Lymphoma, Non-Hodgkin/immunology , Male , Middle Aged , Polymerase Chain Reaction , Retrospective Studies , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , T-Lymphocytes/pathology , Young Adult
2.
Blood ; 119(4): 933-9; quiz 1093, 2012 Jan 26.
Article in English | MEDLINE | ID: mdl-21835953

ABSTRACT

Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE). This prospective, open-label, randomized substudy of a phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients with newly diagnosed MM, treated with lenalidomide and low-dose dexamethasone induction and melphalan-prednisone-lenalidomide consolidation. Overall, 342 patients who did not have clinical indications or contraindications to antiplatelet or anticoagulant therapy were randomly assigned to receive ASA 100 mg/d (n = 176) or LMWH enoxaparin 40 mg/d (n = 166). The incidence of VTE was 2.27% in the ASA group and 1.20% in the LMWH group. Compared with LMWH, the absolute difference in the proportion of VTE was 1.07% (95% confidence interval, -1.69-3.83; P = .452) in the ASA group. Pulmonary embolism was observed in 1.70% of patients in the ASA group and none in the LMWH group. No arterial thrombosis, acute cardiovascular events, or sudden deaths were reported. No major hemorrhagic complications were reported. In previously untreated patients with MM receiving lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative to LMWH thromboprophylaxis.


Subject(s)
Anticoagulants/therapeutic use , Aspirin/therapeutic use , Enoxaparin/therapeutic use , Multiple Myeloma/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Thalidomide/analogs & derivatives , Venous Thromboembolism/prevention & control , Adult , Anticoagulants/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Aspirin/adverse effects , Enoxaparin/adverse effects , Female , Humans , Incidence , Israel/epidemiology , Italy/epidemiology , Lenalidomide , Male , Middle Aged , Platelet Aggregation Inhibitors/adverse effects , Pulmonary Embolism/chemically induced , Pulmonary Embolism/epidemiology , Pulmonary Embolism/prevention & control , Risk Factors , Thalidomide/administration & dosage , Thalidomide/adverse effects , Thalidomide/therapeutic use , Venous Thromboembolism/chemically induced , Venous Thromboembolism/epidemiology , Venous Thrombosis/chemically induced , Venous Thrombosis/epidemiology , Venous Thrombosis/prevention & control
3.
Leuk Lymphoma ; 48(8): 1569-76, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17701589

ABSTRACT

Cryopreservation of ovarian tissue is currently practiced in an attempt to preserve fertility before commencing potentially sterilizing chemotherapy. Clinical and laboratory guidelines are needed to standardize the procedure. Over the last 10 years ovarian tissue was stored in female patients with hematologic malignancies. Patients' records and consultation charts were evaluated, surgical and laboratory reports were revised and ovarian histology was investigated. Fifty-six patients with hematologic malignancies (age 24 +/- 5.5) had cryopreserved ovarian tissue. Thirty-three patients had Hodgkin's disease, 14 non-Hodgkin's lymphoma, 6 acute leukemia, and 3 chronic myelocytic leukemia. Harvesting of ovarian tissue was also performed following previous exposure to chemotherapy (33 patients), 13 of them shortly after the chemotherapy. Partial oophorectomy was the preferred surgical procedure. Fertility was restored with ovarian tissue transplantation in a sterilized patient and following fertility treatment in a patient with very low ovarian reserve. We recommend that indications and timing of ovarian tissue banking should be individualized. Patients previously exposed to chemotherapy can consider ovarian tissue freezing. The extent of tissue removed should take into account the large number of follicles lost and the risk of future sterilization. Tissue handling should enable further investigation of primordial follicles and identification of cancer cells.


Subject(s)
Cryopreservation , Hematologic Neoplasms/therapy , Ovary , Tissue Banks , Tissue Preservation , Adolescent , Adult , Female , Fertility , Hodgkin Disease/therapy , Humans , Infertility, Female , Leukemia/therapy , Lymphoma, Non-Hodgkin/therapy , Pregnancy
4.
J Clin Virol ; 40(2): 156-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17703994

ABSTRACT

BACKGROUND: EBV associated hemophagocytic syndrome (HPS) is an aggressive and potentially life-threatening condition. So far, most EBV associated HPS has been characterized mainly in infants and children in Asian countries. RESULTS: Here, we report six cases of EBV associated HPS occurring in previously healthy adults in a non-endemic area within a short period of 3 years. All patients presented with fever, hepatosplenomegaly and pancytopenia as well as disturbed liver function tests and coagulopathy. Half were diagnosed as having lymphoma. While EBV-specific serological assays were non-diagnostic in four of the six patients, the presence of EBV DNA in plasma allowed the diagnosis of EBV associated HPS in all patients. CONCLUSION: EBV associated HPS may be more prevalent in non-Japanese adults than was previously considered. Screening for hemophagocytic syndrome, in adults as well as in children, should include real-time PCR for EBV.


Subject(s)
Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human/isolation & purification , Lymphohistiocytosis, Hemophagocytic/etiology , Adolescent , Adult , Aged , Antibodies, Viral/blood , DNA, Viral/blood , Epstein-Barr Virus Infections/diagnosis , Female , Hepatomegaly/pathology , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/immunology , Humans , Liver/physiopathology , Lymphohistiocytosis, Hemophagocytic/pathology , Lymphoma/pathology , Male , Pancytopenia/pathology , Splenomegaly/pathology
5.
Ann Surg Oncol ; 13(11): 1372-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17009162

ABSTRACT

BACKGROUND: The management of patients with gastric lymphoma has evolved, with a shift toward nonsurgical treatment. The rates of surgical complications in patients receiving chemotherapy have been insufficiently studied. The objective of this study was to assess the frequency of bleeding, perforation, and gastric outlet obstruction in patients who received chemotherapy as primary treatment for gastric diffuse large B cell lymphoma (DLBCL). METHODS: We reviewed files of all patients with gastric DLBCL who were diagnosed and treated primarily with chemotherapy in our hospital between 1990 and 2005. RESULTS: Eighteen (25%) of 73 patients experienced surgical complications, of whom 6 (8%) underwent surgery. Eight patients (11%), six with active lymphoma, experienced gastric bleeding; one required gastrectomy. Eight patients (11%) developed gastric outlet obstruction, of whom three were treated conservatively, three required surgery, one stopped treatment, and one received further chemotherapy. Six of the eight patients had no evidence of active lymphoma at the time of obstruction. Two additional patients underwent gastrectomy due to resistant or relapsed disease. Gastric perforation was not observed. Median survival was 90 months for the entire series, 94 months for patients with gastric outlet obstruction, and 11.5 months for patients with gastric bleeding. CONCLUSIONS: Given the rate of surgical complications, especially gastric bleeding and gastric outlet obstruction, there is still an important role for the surgical consultant in the treatment of patients with gastric DLBCL receiving chemotherapy. Gastric perforation, although frequently cited as a complication, is in fact rarely observed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gastric Outlet Obstruction/etiology , Gastrointestinal Hemorrhage/etiology , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Stomach Neoplasms/drug therapy , Stomach Rupture/etiology , Adult , Aged , Aged, 80 and over , Female , Humans , Lymphoma, B-Cell/complications , Lymphoma, Large B-Cell, Diffuse/complications , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Retrospective Studies , Stomach Neoplasms/complications , Survival Rate , Treatment Outcome
6.
Exp Gerontol ; 39(4): 507-15, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15050284

ABSTRACT

Many immune functions decline with age and may jeopardize the elderly, as illustrated, for example by the significantly higher mortality rate from influenza in old age. Although innate and humoral immunity are affected by aging, it is the T cell compartment, which manifests most alterations. The mechanisms behind these alterations are still unclear, and several explanations have been offered including thymic involution and Telomere attrition leading to cell senescence. Age related accumulation of mutations has been documented and could serve as an additional mechanism of T cell dysfunction. One effective repair mechanism capable of rectifying errors in DNA replications is the mismatch repair (MMR) system. We previously reported a comparative examination of individual DNA samples from blood cells obtained at 10 year intervals from young and old subjects. We showed significantly higher rates of microsatellite instability (MSI), an indicator of MMR dysfunction in older subjects, compared to young. In the present study we confirm this result, using direct automated sequencing and in addition, we demonstrate that as CD8 lymphocytes from aged individuals, undergo repeated population doublings (PDs) in culture, they develop MSI. CD4 clones that also undergo repeated PDs in culture develop significant MSI as well. Elucidation of this previously unexplored facet of lymphocyte dynamics in relation to aging may help identify novel mechanisms of immunosenescence and pathways that could serve as targets for interventions to restore immune function.


Subject(s)
Aging/genetics , Aging/immunology , Microsatellite Repeats/genetics , T-Lymphocytes/pathology , Adult , Aged , Aged, 80 and over , Base Pair Mismatch/genetics , Base Pair Mismatch/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/pathology , Cellular Senescence/genetics , Cellular Senescence/immunology , DNA Methylation , DNA Repair/genetics , DNA Repair/immunology , Humans , Microsatellite Repeats/immunology , Middle Aged , Promoter Regions, Genetic/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...